Evidence map›Paper›PMID 38851782›Full record

ArticleScientific reports2024

Simultaneous screening of overexpressed genes in breast cancer for oncogenic drivers and tumor dependencies.

Adaobi Mofunanya, Eleanor R Cameron, Christian J Braun, Frank Celeste, Xiaoyu Zhao, Michael T Hemann, Kenneth L Scott, Jinyu Li, Scott Powers

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adaobi MofunanyaDepartment of Pathology, Stony Brook Cancer Center, Stony Brook, NY, 11794, USA.
Eleanor R CameronKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Christian J BraunKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Frank CelesteDepartment of Pathology, Stony Brook Cancer Center, Stony Brook, NY, 11794, USA.
Xiaoyu ZhaoDepartment of Pathology, Stony Brook Cancer Center, Stony Brook, NY, 11794, USA.
Michael T HemannKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Kenneth L ScottDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
Jinyu LiDepartment of Pathology, Stony Brook Cancer Center, Stony Brook, NY, 11794, USA.
Scott PowersDepartment of Pathology, Stony Brook Cancer Center, Stony Brook, NY, 11794, USA. scott.powers@stonybrook.edu.

Funding

Supplement to Multigenic copy number alterationsR01CA217206 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI POWERS, SCOTT · 2017 to 2021
$2.8M
NCI NIH HHS R01 CA217206NIH HHS CA217206
6 · The paper itself

Abstract

There are hundreds of genes typically overexpressed in breast cancer cells and it's often assumed that their overexpression contributes to cancer progression. However, the precise proportion of these overexpressed genes contributing to tumorigenicity remains unclear. To address this gap, we undertook a comprehensive screening of a diverse set of seventy-two genes overexpressed in breast cancer. This systematic screening evaluated their potential for inducing malignant transformation and, concurrently, assessed their impact on breast cancer cell proliferation and viability. Select genes including ALDH3B1, CEACAM5, IL8, PYGO2, and WWTR1, exhibited pronounced activity in promoting tumor formation and establishing gene dependencies critical for tumorigenicity. Subsequent investigations revealed that CEACAM5 overexpression triggered the activation of signaling pathways involving β-catenin, Cdk4, and mTOR. Additionally, it conferred a growth advantage independent of exogenous insulin in defined medium and facilitated spheroid expansion by inducing multiple layers of epithelial cells while preserving a hollow lumen. Furthermore, the silencing of CEACAM5 expression synergized with tamoxifen-induced growth inhibition in breast cancer cells. These findings underscore the potential of screening overexpressed genes for both oncogenic drivers and tumor dependencies to expand the repertoire of therapeutic targets for breast cancer treatment.

Indexed as

Breast NeoplasmsCell ProliferationGene Expression Regulation, NeoplasticAnimalsbeta CateninCell Adhesion MoleculesCell Line, TumorCell Transformation, NeoplasticCyclin-Dependent Kinase 4FemaleHumansOncogenesSignal TransductionTamoxifenTOR Serine-Threonine Kinasesbeta CateninCell Adhesion MoleculesCyclin-Dependent Kinase 4TamoxifenTOR Serine-Threonine Kinases

Identifiers

PMID38851782
PMCPMC11162420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.